HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: The REMOVAL trial.

AbstractAIM:
To determine whether metformin's effects on carotid artery intima-media thickness (cIMT) in type 1 diabetes differ according to smoking status.
METHODS:
Regression model effect estimates for the effect of metformin versus placebo (double-blind) on carotid IMT were calculated as a subgroup analysis of the REMOVAL trial.
RESULTS:
In 428 randomized participants (227 never-smokers, 201 ever-smokers), averaged mean carotid IMT progression (per year) was reduced by metformin versus placebo in never-smokers (-0.012 mm, 95% CI -0.021 to -0.002; p = .0137) but not in ever-smokers (0.003 mm, 95% CI -0.008 to 0.014; p = .5767); and similarly in non-current smokers (-0.008 mm, 95% CI -0.015 to -0.00001; p = .0497) but not in current smokers (0.013 mm, 95% CI -0.007 to 0.032; p = .1887). Three-way interaction terms (treatment*time*smoking status) were significant for never versus ever smoking (p = .0373, prespecified) and non-current versus current smoking (p = .0496, exploratory). Averaged maximal carotid IMT progression (per year) was reduced by metformin versus placebo in never-smokers (-0.020 mm, 95% CI -0.034 to -0.006; p = .0067) but not in ever-smokers (-0.006 mm, 95% CI -0.020 to 0.008; p = .4067), although this analysis was not supported by a significant three-way interaction term.
CONCLUSIONS:
This subgroup analysis of the REMOVAL trial provides additional support for a potentially wider role of adjunct metformin therapy in cardiovascular risk management in type 1 diabetes, particularly for individuals who have never smoked cigarettes.
AuthorsJoseph G Timmons, Nicola Greenlaw, James G Boyle, Nish Chaturvedi, Ian Ford, Martijn C G J Brouwers, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein, Ron Klein, Teik C Ooi, Peter Rossing, Coen D A Stehouwer, Naveed Sattar, Helen M Colhoun, John R Petrie, REMOVAL Study Group
JournalDiabetes, obesity & metabolism (Diabetes Obes Metab) Vol. 23 Issue 6 Pg. 1371-1378 (06 2021) ISSN: 1463-1326 [Electronic] England
PMID33591613 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© 2021 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Chemical References
  • Metformin
Topics
  • Carotid Arteries
  • Carotid Intima-Media Thickness
  • Diabetes Mellitus, Type 1 (complications, drug therapy)
  • Double-Blind Method
  • Humans
  • Metformin (therapeutic use)
  • Risk Factors
  • Smokers
  • Smoking

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: